Eli Lilly reported additional early trial results for VERVE-102, its PCSK9 base editing gene therapy acquired from Verve Therapeutics. In Phase 1b data described by Lilly, a single infusion reduced low-density lipoprotein (LDL) by up to 62%, with reductions sustained for as long as 18 months and no reported treatment-related serious adverse events in the early study. The update follows Lilly’s earlier framing of PCSK9 base editing as a potential one-time approach for patients with genetically elevated cholesterol and early-onset heart disease—aimed at overcoming adherence and access barriers that can blunt outcomes from chronic LDL-lowering therapies. Lilly’s reporting also reinforces investor attention on first-in-human gene editing durability signals as the field seeks clinically meaningful, long-lasting cardiometabolic benefit.